Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12484847 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16597841 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16608860 | 0.90 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16608854 | 0.82 | DHFR (0.40) | KDM4EALDH1A1HPGDKMT2ARAB9A | |
| SCHEMBL3187493 | 0.82 | GRM4 (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3187486 | 0.82 | GRM4 (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16608841 | 0.82 | GRM4 (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17995514 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16597522 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL16597519 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| WO-2015048246-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048246-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2012115479-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | AR, FSHR, ESRRB | KDM4E 1583/4885ALDH1A1 2136/4885HPGD 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.